Veloxis Pharmaceuticals (Veloxis) is a speciality pharmaceutical company focused on the development and commercialization of Envarsus® (LCP-Tacro) for the prevention of organ rejection in kidney transplant patients. All clinical studies for Envarsus®, including two Phase III trials, have successfully been completed and a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in December 2013 seeking approval for the marketing and sale of Envarsus®. Envarsus® has been granted Orphan Drug Status by the FDA.
|Veloxis Announces Action against the FDA
|Veloxis offentliggør at have anlagt retssag mod FDA
|Q3 2014 Audiocast|
|Q3 2014 Interim Report
|Q3 2014 Presentation